Lantern Pharma to Host Glioblastoma Multiforme Web
Post# of 367
(Total Views: 205)
Posted On: 05/19/2022 4:40:22 PM
Lantern Pharma to Host Glioblastoma Multiforme Webinar to Mark Brain Tumor Awareness Month
Last week, Lantern Pharma Inc. announced that it would host a virtual webinar on May 26, 2022, at 12 p.m. ET. Lantern Pharma Inc. is an oncology-focused clinical stage biopharmaceutical firm that is leveraging its proprietary AI and machine learning platform to transform the discovery and development of oncology drugs.
The company’s approach is to deliver the best-in-class outcomes. It is currently developing an ADC program and four drug candidates across nine disclosed tumor targets.
The key opinion leader webinar, which will be held toward the end of Brain Tumor Awareness Month, will mainly focus on glioblastoma multiforme and the potential of the company’s LP-184 drug candidate in treating this malignancy and other cancers of the brain.
Glioblastoma multiforme is one of the most common types of primary tumors of the brain, with estimates showing that roughly 13,000 individuals in America are diagnosed with this particular tumor annually. Patients with these tumors have a poor prognosis, with a median survival of about two years.
The low rate of survival of patients with glioblastoma multiforme is partly brought about by the lack of new and effective therapies that can penetrate the blood-brain barrier. This highlights the need for new treatments that can address this clinically unmet need.
Preclinical studies of Lantern Pharma’s LP-184 formulation have demonstrated potency against both methylated and unmethylated types of glioblastoma multiforme as well as the ability to penetrate the blood-brain barrier.
This Brain Tumor Awareness Month, the biopharmaceutical company hopes to raise awareness and bring support to more than 700,000 individuals in America living with primary brain tumors.
The webinar will feature discussions by Dr. Matthias Holdhoff and Dr. John Laterra, who are both experts in glioblastoma multiforme and brain cancer research and treatment. Holdhoff is an associate professor of oncology and neurological surgery at the School of Medicine, Johns Hopkins University. He has research and clinical expertise in central nervous system lymphomas, malignant gliomas and primary brain cancers. Laterra is the director of the Division of Neuro-Oncology at the School of Medicine, Johns Hopkins University. He specializes in investigating mechanisms of tumor vascular biology, brain tumor malignancy and identification of new glioma therapeutic targets.
These discussions will be accompanied by Dr. Kishor Bhatia, Lantern Pharma’s chief scientific officer, who will expound on the company’s clinical development plans for its LP-184 candidate and the mechanisms targeted by this formulation in various brain cancers.
Once the discussions are completed, a live Q&A session with Bhatia will commence. Parties interested in registering for the webinar can use this link.
The attention being given to primary brain cancers by different entities, including CNS Pharmaceuticals Inc. (NASDAQ: CNSP), suggests that this segment of oncology could soon see a breakthrough resulting in a major transformation in the way patients are currently being treated and the clinical outcomes that they obtain.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Last week, Lantern Pharma Inc. announced that it would host a virtual webinar on May 26, 2022, at 12 p.m. ET. Lantern Pharma Inc. is an oncology-focused clinical stage biopharmaceutical firm that is leveraging its proprietary AI and machine learning platform to transform the discovery and development of oncology drugs.
The company’s approach is to deliver the best-in-class outcomes. It is currently developing an ADC program and four drug candidates across nine disclosed tumor targets.
The key opinion leader webinar, which will be held toward the end of Brain Tumor Awareness Month, will mainly focus on glioblastoma multiforme and the potential of the company’s LP-184 drug candidate in treating this malignancy and other cancers of the brain.
Glioblastoma multiforme is one of the most common types of primary tumors of the brain, with estimates showing that roughly 13,000 individuals in America are diagnosed with this particular tumor annually. Patients with these tumors have a poor prognosis, with a median survival of about two years.
The low rate of survival of patients with glioblastoma multiforme is partly brought about by the lack of new and effective therapies that can penetrate the blood-brain barrier. This highlights the need for new treatments that can address this clinically unmet need.
Preclinical studies of Lantern Pharma’s LP-184 formulation have demonstrated potency against both methylated and unmethylated types of glioblastoma multiforme as well as the ability to penetrate the blood-brain barrier.
This Brain Tumor Awareness Month, the biopharmaceutical company hopes to raise awareness and bring support to more than 700,000 individuals in America living with primary brain tumors.
The webinar will feature discussions by Dr. Matthias Holdhoff and Dr. John Laterra, who are both experts in glioblastoma multiforme and brain cancer research and treatment. Holdhoff is an associate professor of oncology and neurological surgery at the School of Medicine, Johns Hopkins University. He has research and clinical expertise in central nervous system lymphomas, malignant gliomas and primary brain cancers. Laterra is the director of the Division of Neuro-Oncology at the School of Medicine, Johns Hopkins University. He specializes in investigating mechanisms of tumor vascular biology, brain tumor malignancy and identification of new glioma therapeutic targets.
These discussions will be accompanied by Dr. Kishor Bhatia, Lantern Pharma’s chief scientific officer, who will expound on the company’s clinical development plans for its LP-184 candidate and the mechanisms targeted by this formulation in various brain cancers.
Once the discussions are completed, a live Q&A session with Bhatia will commence. Parties interested in registering for the webinar can use this link.
The attention being given to primary brain cancers by different entities, including CNS Pharmaceuticals Inc. (NASDAQ: CNSP), suggests that this segment of oncology could soon see a breakthrough resulting in a major transformation in the way patients are currently being treated and the clinical outcomes that they obtain.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
(0)
(0)